Beijing will soon begin supplying Pfizer’s Covid-19 medication Paxlovid to the community health centres in the next days as Covid instances in China continue to rise.
Surge in Covid cases in China, it might soon start distributing Pfizer’s Covid-19 drug Paxlovid to community health centres
After receiving training, community doctors would give the medication to Covid-19 patients and also spread instructions on how to use it, according to the government-run China News Service.
Paxlovid remains the only foreign Covid drug to be approved by China for nationwide use
The only foreign Covid medication that has received nationwide approval from China’s regulator is Paxlovid, however getting access to the drug can be difficult.
According to media sources, China’s National Health Security Administration warned Pfizer on Sunday that its oral medication Paxlovid, which is used to treat Covid-19, could not be included to the “register of medications in the basic medical insurance” because the company’s citation was too high.
Also Read: Chinese physicians urged not to list Covid-19 as the primary cause of death
Demand for Indian generic variations via Chinese e-commerce platform has gone up
In the midst of the ongoing Covid surge in China, demand for Indian generic drugs has surged despite experts’ warnings that questionable varieties of those medications were overtaking the market.
The large and quick supply of Paxlovid has increased demand for Indian generic alternatives sold throu gh Chinese e-commerce sites.
“Primovir, Paxista, Molnunat, and Molnatris, at least four generic Covid drug made in India, have recently been made available for purchase on Chinese e-commerce sites. While the other two are generic variants of Molnipiravir, Primovir and Paxista are both Paxlovid versions “Sixth Tone, a Chinese news source, said.
China abruptly ended its “Zero Covid” policy last month after nearly three years of lockdowns, quarantines, and mass testing in response to nationwide protests against it.
The sudden policy shift has caused panicky purchases of fever and cold medicines, leading to severe shortages at pharmacies and on internet marketplaces. According to sources, lengthy lines are now typical outside fever clinics and hospital wards in Beijing, the nation’s capital, and abroad.
Sources stated that after China abandoned its “Zero Covid” policy approximately two weeks ago, regional coronavirus infection rates point to explosive breakouts and overburdened healthcare systems.
However, because official numbers from the central government are still few, the scope and severity of the nation’s first countrywide outbreak remain unknown.
China’s healthcare system under tremendous strain
According to reports, the 1.4 billion-person healthcare system in China is under a great deal of stress as a result of the high costs of medications made by international pharmaceutical giants.
A report stated that all hospitals, both public and private, are currently full and that additional patients cannot be admitted.
Receiving a bed is impossible as people are jam-packed into hallways and aisles and sprawled out on soggy floors, according to the study.
According to the research, the majority of patients are left to their own devices outside of the government’s health system, and millions of people lack access to medication, oxygen, respiratory equipment, and other medical supplies.
It stated that the only thing available to them was a medical drip.
Various reports have stated that the majority of older patients are experiencing various health issues, mainly lung infections, and that concerns about the elderly dying from the illness or other comorbidities are growing as a result of these shortcomings.
Also Read: New Case Of XBB 1.5 Strain, Behind US Covid Surge, Detected In India
Keep watching our YouTube Channel ‘DNP INDIA’. Also, please subscribe and follow us on FACEBOOK, INSTAGRAM, and TWITTER.